Charles Schwab Investment Management Inc. Trims Stake in Senseonics Holdings, Inc. (NYSE:SENS)

Charles Schwab Investment Management Inc. lowered its position in Senseonics Holdings, Inc. (NYSE:SENS) by 1.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,064,856 shares of the company’s stock after selling 45,234 shares during the period. Charles Schwab Investment Management Inc. owned 0.57% of Senseonics worth $1,072,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. GSA Capital Partners LLP bought a new stake in shares of Senseonics in the 3rd quarter worth approximately $117,000. Symmetry Partners LLC purchased a new position in Senseonics during the third quarter valued at $164,000. Finally, Cubist Systematic Strategies LLC boosted its holdings in Senseonics by 25.9% in the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after acquiring an additional 85,501 shares in the last quarter. Hedge funds and other institutional investors own 12.36% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Frederick T. Sullivan purchased 124,933 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were purchased at an average cost of $0.38 per share, for a total transaction of $47,474.54. Following the purchase, the chief financial officer now directly owns 2,478,844 shares in the company, valued at approximately $941,960.72. This represents a 5.31 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Timothy T. Goodnow acquired 315,000 shares of Senseonics stock in a transaction that occurred on Tuesday, December 10th. The shares were purchased at an average price of $0.31 per share, with a total value of $97,650.00. Following the transaction, the chief executive officer now owns 11,310,355 shares of the company’s stock, valued at $3,506,210.05. The trade was a 2.86 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research firms have recently issued reports on SENS. StockNews.com started coverage on Senseonics in a research report on Wednesday. They issued a “sell” rating for the company. HC Wainwright reaffirmed a “buy” rating and issued a $2.00 target price on shares of Senseonics in a report on Friday, November 15th.

Senseonics Stock Performance

Shares of SENS opened at $0.42 on Wednesday. Senseonics Holdings, Inc. has a 12 month low of $0.25 and a 12 month high of $0.75. The business’s fifty day simple moving average is $0.33 and its two-hundred day simple moving average is $0.37. The company has a current ratio of 2.47, a quick ratio of 2.38 and a debt-to-equity ratio of 59.17. The company has a market cap of $249.74 million, a price-to-earnings ratio of -3.23 and a beta of 0.77.

Senseonics Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.